Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease

We studied the autoradiographic densities of all pharmacologically characterised muscarinic receptors (MR) in frontal, temporal, and visual cortex, hippocampal formation, and striatum in autopsied brains from 19 histopathologically verified patients of Alzheimer's disease (AD) and in matched controls. Almost all (16 of 19) of the AD cases were severe. In AD brains, total MR, M1, and M3 MR subtypes were found to be significantly decreased in entorhinal cortex and in most hippocampal strata. Total MR and M1 receptors were also significantly reduced in visual area and in frontal cortex of AD brains, respectively. M2 receptors were significantly reduced over hippocampal formation but increased significantly in striatum of AD brains as compared with controls. M3 receptors in AD were in the range of controls in neocortex and striatum, whereas the M4 receptor subtype was also preserved in all brain regions in AD brains when compared with controls. This is the first autoradiographic study analysing the distribution of all MR subtypes in AD brains. These changes in MR densities concur with the general pattern of neuronal degeneration occurring in AD brains and partly explain the poor response of AD cognitive decline to present cholinergic supplementation therapies. Although M3 and M4 MR were labelled with nonselective approaches, the preservation of M4 and to a lesser degree M3 MR subtypes in AD brains could open an alternative way for the symptomatic therapy of AD dementia. Synapse 26:341–350, 1997. © 1997 Wiley‐Liss Inc.

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[2]  E. Perry,et al.  Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[3]  C. Nemeroff,et al.  Overexpression of the high affinity choline transporter in cortical regions affected by Alzheimer's disease. Evidence from rapid autopsy studies. , 1994, The Journal of clinical investigation.

[4]  E. Bird,et al.  Pre- and postsynaptic neurochemical alterations in Alzheimer's disease , 1978, Brain Research.

[5]  P. Aagaard,et al.  Pharmacological characterization of the rat hippocampal muscarinic autoreceptor. , 1993, The Journal of pharmacology and experimental therapeutics.

[6]  E K Perry,et al.  Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. , 1978, British medical journal.

[7]  Robert H. Perry,et al.  Neurotransmitter enzyme abnormalities in senile dementia Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue , 1977, Journal of the Neurological Sciences.

[8]  Á. Pazos,et al.  Characterization of [3H]Hemicholinium‐3 Binding Sites in Human Brain Membranes: A Marker for Presynaptic Cholinergic Nerve Terminals , 1990, Journal of neurochemistry.

[9]  E. Perry,et al.  Cholinergic Receptors in Cognitive Disorders , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[10]  D. Price,et al.  Muscarinic and nicotinic cholinergic binding sites in alzheimer's disease cerebral cortex , 1987, Brain Research.

[11]  R. E. Baker,et al.  Development of dorsal root III afferent fibres in postmetamorphic juveniles of the frog Discoglossus pictus , 1977, Neuroscience.

[12]  M. Raiteri,et al.  Enhancement of glycine release from human brain cortex synaptosomes by acetylcholine acting at M4 muscarinic receptors. , 1993, The Journal of pharmacology and experimental therapeutics.

[13]  P. Davies Neurotransmitter-related enzymes in senile dementia of the alzheimer type , 1979, Brain Research.

[14]  E. Perry,et al.  Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[15]  Á. Pazos,et al.  Effects of freezing storage time on the density of muscarinic receptors in the human postmortem brain: an autoradiographic study in control and Alzheimer's disease brain tissues , 1996, Brain Research.

[16]  Á. Pazos,et al.  Selective cortical decrease of high-affinity choline uptake carrier in Alzheimer's disease: An autoradiographic study using3H-hemicholinium-3 , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[17]  J. Palacios,et al.  Advances and limitations of the molecular neuroanatomy of cholinergic receptors: the example of multiple muscarinic receptors. , 1993, Progress in brain research.

[18]  J. Palacios,et al.  Muscarinic M2‐selective ligands also recognize M4 receptors in the rat brain: Evidence from combined in situ hybridization and receptor autoradiography , 1992, Synapse.

[19]  P. Mcgeer,et al.  Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain , 1984, Neurology.

[20]  J. Coyle,et al.  Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis , 1981, Annals of neurology.

[21]  A. Shetter,et al.  Cortical biopsy in Alzheimer's disease: Diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations , 1992 .

[22]  Mark P. Mattson,et al.  β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease , 1993, Trends in Neurosciences.

[23]  D. Mash,et al.  Differential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer's Disease , 1995, Journal of neurochemistry.

[24]  H. Fibiger Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence , 1991, Trends in Neurosciences.

[25]  J. Coyle,et al.  Basal Forebrain Cholinergic Neurons and Alzheimer’s Disease , 1988 .

[26]  A. Paetau,et al.  A post-mortem comparison of the cortical cholinergic system in Alzheimer's disease and Pick's disease , 1983, Journal of the Neurological Sciences.

[27]  Á. Pazos,et al.  High-affinity choline uptake carrier in Alzheimer's disease: implications for the cholinergic hypothesis of dementia , 1991, Brain Research.

[28]  E. Perry The cholinergic hypothesis--ten years on. , 1986, British medical bulletin.

[29]  D. Mash,et al.  Comparison of the concentration of messenger RNA encoding four muscarinic receptor subtypes in control and Alzheimer brains. , 1992, Brain research. Molecular brain research.

[30]  D. Bowen,et al.  NEOCORTICAL CHOLINERGIC NEURONS IN ELDERLY PEOPLE , 1977, The Lancet.

[31]  S. Jenni-Eiermann,et al.  Studies on neurotransmitter binding in senile dementia. Comparison of Alzheimer's and mixed vascular-Alzheimer's dementias. , 1984, Gerontology.

[32]  S. Gauthier,et al.  Differential Alteration of Various Cholinergic Markers in Cortical and Subcortical Regions of Human Brain in Alzheimer's Disease , 1988, Journal of neurochemistry.

[33]  D. Mash,et al.  Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. , 1985, Science.

[34]  J. Coyle,et al.  Nicotinic acetylcholine binding sites in Alzheimer's disease , 1986, Brain Research.

[35]  J. Palacios,et al.  Quantitative light microscopic autoradiographic localization of cholinergic muscarinic receptors in the human brain: Brainstem , 1984, Neuroscience.

[36]  T. Bonner,et al.  Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. , 1989, Molecular pharmacology.

[37]  T. Crow,et al.  CORTICAL MUSCARINIC RECEPTOR SUBTYPES AND ALZHEIMER'S DISEASE , 1982, The Lancet.

[38]  C. Marsden,et al.  BRAIN MUSCARINIC RECEPTORS IN ALZHEIMER'S AND PARKINSON'S DISEASES , 1989, The Lancet.

[39]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[40]  J. Rinne,et al.  A postmortem study of brain nicotinic receptors in Parkinson's and Alzheimer's disease , 1991, Brain Research.

[41]  J. Christophe,et al.  Binding of selective antagonists to four muscarinic receptors (M1 to M4) in rat forebrain. , 1990, Molecular pharmacology.

[42]  D. Mash,et al.  Loss of high‐affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies , 1991, Annals of neurology.

[43]  D. Flynn,et al.  Diminished muscarinic receptor-stimulated [3H]-PIP2 hydrolysis in Alzheimer's disease. , 1993, Life sciences.

[44]  D. Price,et al.  Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease , 1988, Neurology.

[45]  A. Nordberg,et al.  Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists , 1992, Brain Research.

[46]  J. Rinne,et al.  Brain muscarinic receptors in senile dementia , 1985, Brain Research.

[47]  S. Gauthier,et al.  Neurotransmitter and Receptor Deficits in Senile Dementia of the Alzheimer Type , 1986, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[48]  T. Bonner The molecular basis of muscarinic receptor diversity , 1989, Trends in Neurosciences.

[49]  J. Palacios Autoradiographic localization of muscarinic cholinergic receptors in the hippocampus of patients with senile dementia , 1982, Brain Research.

[50]  S. Mirra,et al.  Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients , 1987, Neurology.

[51]  D. Mash,et al.  Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease. , 1995, Molecular and chemical neuropathology.

[52]  Z. Khachaturian Diagnosis of Alzheimer's disease. , 1985, Archives of neurology.

[53]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[54]  S. Shimohama,et al.  Signal transduction mechanisms in Alzheimer disease. , 1995, Alzheimer disease and associated disorders.

[55]  D. Mash,et al.  Selective labeling and localization of the M4 (m4) muscarinic receptor subtype. , 1994, Molecular pharmacology.

[56]  Peter Davies,et al.  Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer's-type dementia brains , 1977, Brain Research.

[57]  S. Gauthier,et al.  Comparative Alterations of Nicotinic and Muscarinic Binding Sites in Alzheimer's and Parkinson's Diseases , 1992, Journal of neurochemistry.

[58]  J. Growdon,et al.  Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. , 1993, The Journal of biological chemistry.

[59]  C. Nemeroff,et al.  Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[60]  A. Michel,et al.  Direct labeling of rat M3-muscarinic receptors by [3H]4DAMP. , 1989, European journal of pharmacology.

[61]  B. Winblad,et al.  Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type , 1986, Neuroscience Letters.

[62]  D. Araujo,et al.  Characterization and quantitative autoradiographic distribution of [3H]acetylcholine muscarinic receptors in mammalian brain. Apparent labelling of an M2-like receptor sub-type , 1989, Neuroscience.

[63]  G. Vauquelin,et al.  Muscarinic cholinergic receptor subtypes in normal human brain and Alzheimer's presenile dementia , 1987, Journal of the Neurological Sciences.

[64]  S. Gauthier,et al.  Characterization and autoradiographic distribution of [3H]AF-DX 384 binding to putative muscarinic M2 receptors in the rat brain. , 1992, European journal of pharmacology.

[65]  R. Quirion,et al.  Heterogeneous binding of [3H]4‐DAMP to muscarinic cholinergic sites in the rat brain: Evidence from membrane binding and autoradiographic studies , 1991, Synapse.

[66]  J. Growdon,et al.  Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. , 1992, Science.

[67]  H. Happe,et al.  High‐Affinity Choline Transport Sites: Use of [3H]Hemicholinium‐3 as a Quantitative Marker , 1993, Journal of neurochemistry.

[68]  T. Taniguchi,et al.  Changes in Nicotinic and Muscarinic Cholinergic Receptors in Alzheimer‐Type Dementia , 1986, Journal of neurochemistry.

[69]  D. Spencer,et al.  Direct autoradiographic determination of M1 and M2 muscarinic acetylcholine receptor distribution in the rat brain: Relation to cholinergic nuclei and projections , 1986, Brain Research.

[70]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[71]  P. Robberecht,et al.  Kinetic studies of [3H]-N-methylscopolamine binding to muscarinic receptors in the rat central nervous system: evidence for the existence of three classes of binding sites. , 1986, Molecular pharmacology.

[72]  J. Palacios,et al.  Muscarinic cholinergic receptor subtypes in the human brain. II. Quantitative autoradiographic studies , 1986, Brain Research.

[73]  J. Wess,et al.  Antagonist binding profiles of five cloned human muscarinic receptor subtypes. , 1991, The Journal of pharmacology and experimental therapeutics.

[74]  Á. Pazos,et al.  Autoradiographic distribution of [3H]hemicholinium-3 binding sites in human brain , 1989, Brain Research.

[75]  J. Rinne,et al.  Brain muscarinic receptor subtypes are differently affected in Alzheimer's disease and Parkinson's disease , 1989, Brain Research.

[76]  D. Mash,et al.  Distinct kinetic binding propeties of N‐[3H]‐methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain , 1993, Synapse.

[77]  B. Winblad,et al.  Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia , 1992, Journal of neuroscience research.

[78]  H. Henke,et al.  Cholinergic receptor binding and autoradiography in brains of non-neurological and senile dementia of Alzheimer-type patients , 1983, Brain Research.

[79]  J. Palacios,et al.  Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer's disease: an autoradiographic study , 1988, Brain Research.

[80]  D L Price,et al.  Alzheimer's disease: a disorder of cortical cholinergic innervation. , 1983, Science.

[81]  D. Irving,et al.  Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology , 1995, Neuroscience.